To further dissect the contribution of IL2 to anti-HER2 mAbs-induced ADCC, we took advantage of our HER2+ 3DiBC preclinical tumor model that we treated with trastuzumab and recombinant human (rh) IL2. The gene discussed is IL2; the disease is neoplasm.